At the news
? BULLISHIMPACT 8/10 8-K filed Jul 14, 2026 at 06:30 ET
Spero Therapeutics in-licensed SP001 (IBI355), a Phase 2-ready anti-CD40L antibody, from Innovent Biologics for $35M upfront and up to ~$1.1B in milestones + tiered royalties, marking a strategic pivot to immunology. Concurrently, it secured $105M non-recourse, non-dilutive royalty financing backed by future Utebzi (tebipenem pivoxil) milestones and royalties from GSK, extending cash runway into 2H 2029. The company plans to initiate a Phase 2 trial in IgG4-RD in Q2 2027.
- Exclusive license for SP001 (IBI355) from Innovent, covering global rights ex-Greater China
- $35M upfront payment to Innovent; up to $1.05B in development, regulatory, and commercial milestones
- $105M non-recourse financing from HCRx (KKR), backed by a portion of GSK's Utebzi milestone/royalty payments
- Cash runway extended into second half of 2029
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access